through the activation of SIGMAR1
Our proprietary SIGMACEPTOR™ Discovery Platform produces small molecule therapeutic candidates, like ANAVEX®2-73, with novel modes of action.
SIGMAR1 prevents toxic RNA from translating into proteins
ANAVEX®2-73 bound to SIGMAR1
SIGMAR1 protects healthy gene expression through Chromatin Remodeling
When activated by SIGMAR1 agonists, like ANAVEX®2-73, SIGMAR1 reduces cellular stress before and after RNA gene transcription. Studies confirm the predictive biomarker of response established through SIGMAR1 mRNA expression.